Characterization of Anaphylaxis After Ecallantide Treatment of Hereditary Angioedema Attacks

Craig, Timothy J.; Li, H. Henry; Riedl, Marc A.; Bernstein, Jonathan A.; Lumry, William R.; MacGinnitie, Andrew J.; Stolz, Leslie E.; Biedenkapp, Joseph C.; Chyung, Yung

doi:10.1016/j.jaip.2014.09.001

Cited by 35 publications

(25 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is administered subcutaneously as a 30 mg dose 97. Hypersensitivity, including anaphylaxis, is a known risk of ecallantide treatment and occurs in 3% of treatments; no deaths are reported 108. Because of the anaphylaxis risk, this drug should be administered only by a healthcare professional who has medical knowledge in the management of anaphylaxis.…”

Section: Resultsmentioning

confidence: 99%

International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency

Farkas

Martinez‐Saguer²,

Bork

et al. 2016

Allergy

177

308

View full text Add to dashboard Cite

BackgroundThe consensus documents published to date on hereditary angioedema with C1 inhibitor deficiency (C1‐INH‐HAE) have focused on adult patients. Many of the previous recommendations have not been adapted to pediatric patients. We intended to produce consensus recommendations for the diagnosis and management of pediatric patients with C1‐INH‐HAE.MethodsDuring an expert panel meeting that took place during the 9th C1 Inhibitor Deficiency Workshop in Budapest, 2015 (www.haenet.hu), pediatric data were presented and discussed and a consensus was developed by voting.ResultsThe symptoms of C1‐INH‐HAE often present in childhood. Differential diagnosis can be difficult as abdominal pain is common in pediatric C1‐INH‐HAE, but also commonly occurs in the general pediatric population. The early onset of symptoms may predict a more severe subsequent course of the disease. Before the age of 1 year, C1‐INH levels may be lower than in adults; therefore, it is advisable to confirm the diagnosis after the age of one year. All neonates/infants with an affected C1‐INH‐HAE family member should be screened for C1‐INH deficiency. Pediatric patients should always carry a C1‐INH‐HAE information card and medicine for emergency use. The regulatory approval status of the drugs for prophylaxis and for acute treatment is different in each country. Plasma‐derived C1‐INH, recombinant C1‐INH, and ecallantide are the only agents licensed for the acute treatment of pediatric patients. Clinical trials are underway with additional drugs. It is recommended to follow up patients in an HAE comprehensive care center.ConclusionsThe pediatric‐focused international consensus for the diagnosis and management of C1‐INH‐HAE patients was created.

show abstract

Section: Resultsmentioning

confidence: 99%

International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency

Farkas

Martinez‐Saguer²,

Bork

et al. 2016

Allergy

177

308

View full text Add to dashboard Cite

show abstract

“…The main safety concern is potentially serious hypersensitivity reactions, including anaphylaxis, which was reported in 3% to 4% of treated patients. The drug, therefore, should only be administered by a healthcare professional with appropriate medical support to manage anaphylaxis …”

Section: Therapymentioning

confidence: 99%

The international WAO/EAACI guideline for the management of hereditary angioedema—The 2017 revision and update

Maurer

Magerl

Ansotegui

et al. 2018

Allergy

470

974

View full text Add to dashboard Cite

Hereditary Angioedema (HAE) is a rare and disabling disease. Early diagnosis and appropriate therapy are essential. This update and revision of the global guideline for HAE provides up‐to‐date consensus recommendations for the management of HAE. In the development of this update and revision of the guideline, an international expert panel reviewed the existing evidence and developed 20 recommendations that were discussed, finalized and consented during the guideline consensus conference in June 2016 in Vienna. The final version of this update and revision of the guideline incorporates the contributions of a board of expert reviewers and the endorsing societies. The goal of this guideline update and revision is to provide clinicians and their patients with guidance that will assist them in making rational decisions in the management of HAE with deficient C1‐inhibitor (type 1) and HAE with dysfunctional C1‐inhibitor (type 2). The key clinical questions covered by these recommendations are: (1) How should HAE‐1/2 be defined and classified?, (2) How should HAE‐1/2 be diagnosed?, (3) Should HAE‐1/2 patients receive prophylactic and/or on‐demand treatment and what treatment options should be used?, (4) Should HAE‐1/2 management be different for special HAE‐1/2 patient groups such as pregnant/lactating women or children?, and (5) Should HAE‐1/2 management incorporate self‐administration of therapies and patient support measures?

show abstract

“…A retrospective review of the clinical trials figured out that anaphylactic reactions after ecallantide exposure were induced by type I hypersensitivity reactions. As other recombinant proteins, it is immunogenic, but anti-ecallantide or anti-Pichia pastoris IgE antibodies were not found to be reliably associated with anaphylaxis and the clinical efficacy of ecallantide in treating HAE attacks did not appear to be affected by anti-ecallantide antibody positivity [53].…”

Section: Plasma Kallikrein Inhibitormentioning

confidence: 96%

The safety of treatments for angioedema with hereditary C1 inhibitor deficiency

Zanichelli

Andreoli

et al. 2015

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

show abstract

Characterization of Anaphylaxis After Ecallantide Treatment of Hereditary Angioedema Attacks

Abstract: Anaphylaxis episodes after subcutaneous ecallantide exposure have clinical features suggestive of type I hypersensitivity reactions. However, anti-ecallantide or anti-P pastoris IgE antibody status was not found to be reliably associated with anaphylaxis.

Cited by 35 publications

References 15 publications

International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency

International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency

The international WAO/EAACI guideline for the management of hereditary angioedema—The 2017 revision and update

The safety of treatments for angioedema with hereditary C1 inhibitor deficiency

Contact Info

Product

Resources

About